170 related articles for article (PubMed ID: 12468829)
1. Anti-tumour necrosis factor therapy associated with cutaneous vasculitis.
Livermore PA; Murray KJ
Rheumatology (Oxford); 2002 Dec; 41(12):1450-2. PubMed ID: 12468829
[No Abstract] [Full Text] [Related]
2. Granulomatous disease in a child treated with etanercept.
Alhajri M; Aljumaah S; Aleyouni Y; Al-Qahtani F; Alhazzaa S; Al-Mayouf SM
Int J Rheum Dis; 2013 Aug; 16(4):472-4. PubMed ID: 23826822
[No Abstract] [Full Text] [Related]
3. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases.
Fujikawa K; Kawakami A; Hayashi T; Iwamoto N; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Ida H; Origuchi T; Eguchi K
Mod Rheumatol; 2010 Feb; 20(1):86-9. PubMed ID: 19812889
[TBL] [Abstract][Full Text] [Related]
4. The TREAT study - trial or tribulation?
Lehman TJ
J Rheumatol; 2014 Jun; 41(6):1038-9. PubMed ID: 24882847
[No Abstract] [Full Text] [Related]
5. Treating leukocytoclastic vasculitis associated with etanercept therapy. Is it necessary to stop etanercept?
Juan A; Ribas B; Nadal C; Ros I
J Rheumatol; 2005 Oct; 32(10):2061; author reply 2061-2. PubMed ID: 16206372
[No Abstract] [Full Text] [Related]
6. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis.
Nerome Y; Imanaka H; Nonaka Y; Takei S
Mod Rheumatol; 2007; 17(6):526-8. PubMed ID: 18084710
[TBL] [Abstract][Full Text] [Related]
7. New-onset psoriasis associated with etanercept therapy.
Chen LA; Su LH; Chang YJ; Hsu YL; Tsai TH
J Dermatol; 2010 Apr; 37(4):378-80. PubMed ID: 20507411
[No Abstract] [Full Text] [Related]
8. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis.
Liu SW; Velez NF; Lam C; Femia A; Granter SR; Townsend HB; Vleugels RA
JAMA Dermatol; 2013 Oct; 149(10):1204-8. PubMed ID: 23986394
[TBL] [Abstract][Full Text] [Related]
9. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.
Mor A; Bingham CO; Barisoni L; Lydon E; Belmont HM
J Rheumatol; 2005 Apr; 32(4):740-3. PubMed ID: 15801034
[TBL] [Abstract][Full Text] [Related]
10. Aortitis during etanercept therapy for ankylosing spondylitis: finding the culprit.
Verhoeven F; Bossert M; Lohse-Walliser A; Balblanc JC
Joint Bone Spine; 2012 Oct; 79(5):524-6. PubMed ID: 22575065
[No Abstract] [Full Text] [Related]
11. Juvenile idiopathic arthritis: current and future treatment options.
Martini G; Zulian F
Expert Opin Pharmacother; 2006 Mar; 7(4):387-99. PubMed ID: 16503811
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis.
Lepore L; Marchetti F; Facchini S; Leone V; Ventura A
Clin Exp Rheumatol; 2003; 21(2):276-7. PubMed ID: 12747299
[No Abstract] [Full Text] [Related]
13. Radiologic Improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept.
Tse SM; Laxer RM; Babyn PS; Doria AS
J Rheumatol; 2006 Jun; 33(6):1186-8. PubMed ID: 16755667
[TBL] [Abstract][Full Text] [Related]
14. Pediatric rheumatology: JIA, treatment and possible risk of malignancies.
Ruperto N; Martini A
Nat Rev Rheumatol; 2011 Jan; 7(1):6-7. PubMed ID: 21135880
[No Abstract] [Full Text] [Related]
15. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
[TBL] [Abstract][Full Text] [Related]
16. [Recommendations by the Pediatric and Adolescent Rheumatology Study Committee on therapy with Etanercept (p75 TNF-alpha receptor immunoglobulin fusion protein. Pharmacotherapy Committee].
Horneff G; Forster J; Seyberth HW; Michels H;
Z Rheumatol; 2000 Dec; 59(6):365-9. PubMed ID: 11201000
[No Abstract] [Full Text] [Related]
17. [Biologicals in the treatment of rheumatic diseases].
Scherer HU; Burmester GR
Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270
[No Abstract] [Full Text] [Related]
18. Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis.
ten Cate R; van Suijlekom-Smit LW; Brinkman DM; Bekkering WP; Jansen-van Wijngaarden CJ; Vossen JM
Rheumatology (Oxford); 2002 Feb; 41(2):228-9. PubMed ID: 11886975
[No Abstract] [Full Text] [Related]
19. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors.
Wallace CA; Giannini EH; Spalding SJ; Hashkes PJ; O'Neil KM; Zeft AS; Szer IS; Ringold S; Brunner HI; Schanberg LE; Sundel RP; Milojevic DS; Punaro MG; Chira P; Gottlieb BS; Higgins GC; Ilowite NT; Kimura Y; Johnson A; Huang B; Lovell DJ;
J Rheumatol; 2014 Jun; 41(6):1163-70. PubMed ID: 24786928
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor necrosis factor therapy is tolerated in an individual with homozygous complement C2 deficiency.
Momeni M; Mehta AP; Katz JD
J Clin Rheumatol; 2005 Jun; 11(3):180-2. PubMed ID: 16357744
[No Abstract] [Full Text] [Related]
[Next] [New Search]
